EUVIMEDOpdag EUVIMED
ÜbersichtsarbeitOpen access · CC BY-NC-ND 4.0

Blood biomarkers in ALS : challenges, applications and novel frontiers

Ellie Sturmey, Andrea Malaspina

Acta Neurologica Scandinavica · 2022-10 · 146 (4) · 375-388

DOI: 10.1111/ane.13698 ↗

At a glance

Übersichtsarbeit in Acta Neurologica Scandinavica, published online on 2022-09-26. Written by Ellie Sturmey and 1 co-authors. Institution: Centre of Neuroscience, Surgery and Trauma, Queen Mary University of London, London, UK. Major MEDLINE topics: Amyotrophic Lateral Sclerosis, Motor Neuron Disease. Cited 59 times so far (Crossref); 124 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: Wellcome Trust, Motor Neurone Disease Association.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Amyotrophic lateral sclerosis (ALS) is the most common motor neuron disease among adults. With diagnosis reached relatively late into the disease process, extensive motor cell loss narrows the window for therapeutic opportunities. Clinical heterogeneity in ALS and the lack of disease-specific biomarkers have so far led to large-sized clinical trials with long follow-up needed to define clinical outcomes. In advanced ALS patients, there is presently limited scope to use imaging or invasive cerebrospinal fluid (CSF) collection as a source of disease biomarkers. The development of more patient-friendly and accessible blood biomarker assays is hampered by analytical hurdles like the matrix effect of blood components. However, blood also provides the opportunity to identify disease-specific adaptive changes of the stoichiometry and conformation of target proteins and the endogenous immunological response to low-abundance brain peptides, such as neurofilaments (Nf). Among those biomarkers under investigation in ALS, the change in concentration before or after diagnosis of Nf has been shown to aid prognostication and to allow the a priori stratification of ALS patients into smaller sized and clinically more homogeneous cohorts, supporting more affordable clinical trials. Here, we discuss the technical hurdles affecting reproducible and sensitive biomarker measurement in blood. We also summarize the state of the art of non-CSF biomarkers in the study of prognosis, disease progression, and treatment response. We will then address the potential as disease-specific biomarkers of the newly discovered cryptic peptides which are formed down-stream of TDP-43 loss of function, the hallmark of ALS pathobiology.

Subjects

MeSH terms (MEDLINE)

Amyotrophic Lateral SclerosisMotor Neuron DiseaseAdultBiomarkersDNA-Binding ProteinsHumansPrognosis

Author keywords

amyotrophic lateral sclerosisblood matrix effectclinical trialsneurofilamentspharmacodynamic biomarkersprognosis

Substances

BiomarkersDNA-Binding Proteins

Authors and institutions

  • Centre of Neuroscience, Surgery and Trauma, Queen Mary University of London, London, UK.
  • Queen Square Institute of Neurology, University College London, London, UK.

Funding

  • Wellcome Trust
  • Motor Neurone Disease Association

Cite

APA

Sturmey, E., & Malaspina, A. (2022). Blood biomarkers in ALS : challenges, applications and novel frontiers. Acta Neurologica Scandinavica, 146(4), 375-388. https://doi.org/10.1111/ane.13698

Vancouver

Sturmey E, Malaspina A. Blood biomarkers in ALS : challenges, applications and novel frontiers. Acta Neurologica Scandinavica. 2022;146(4):375-388. doi:10.1111/ane.13698

BibTeX
@article{Sturmey2022,
  author = {Sturmey, Ellie and Malaspina, Andrea},
  title = {Blood biomarkers in ALS : challenges, applications and novel frontiers},
  journal = {Acta Neurologica Scandinavica},
  year = {2022},
  volume = {146},
  number = {4},
  pages = {375--388},
  doi = {10.1111/ane.13698}
}
Start for free →